Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy ...

The expression of MICA/B cell-surface proteins is induced by cellular stress ... or other attributes to warrant further ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello, ladies and gentlemen, and welcome to the Autolus ...

Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C ...

(Created with Biorender.com) ArcZ, small RNA that regulates ArcA/B regulon; DinB, DNA polymerase IV named for its DNA Damage, ...

In the healthcare sector, companies often work towards crucial events or milestones that can drive significant changes in a ...

Q3 2024 Earnings Call Transcript November 5, 2024 Operator: Good morning, everyone, and welcome to the Cellectis Third ...

This regulatory milestone is the second time BTD has been granted ... including up to 20 times higher risk of developing B-cell lymphomas when compared to the general population. Patients with high ...

Researchers successfully tested the safety and preliminary efficacy of stem-cell-derived corneal implants, showing promise ...

Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice ...

Imugene stocks well placed to grow with clinical progress on azer-cel CAR T-cell therapy and strong cash position, say analysts ...